048410.KQ
Hyundai Bioscience Co., Ltd.
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 6,050.00
−0.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.3B | 3.5B | 15.1B | 9.5B | 7.9B |
| Cost of Revenue | 4.0B | 4.5B | 3.2B | 4.4B | 5.9B |
| Gross Profit | (704.5M) | (1.0B) | 11.9B | 5.0B | 1.9B |
| Operating Expenses | |||||
| R&D Expense | 10.1B | 6.9B | 3.1B | 6.4B | 16.5B |
| SG&A Expense | 8.3B | 5.4B | 3.4B | 3.4B | 11.8B |
| General & Admin Expense | 4.9B | 740.9M | 835.8M | 734.1M | 786.8M |
| Selling & Marketing Expense | 1.3B | 4.7B | 2.5B | 2.7B | 2.0B |
| Other Expenses | 4.9B | 4.8B | 4.7B | 5.0B | (947.9K) |
| Total Operating Expenses | 18.9B | 17.1B | 11.1B | 14.8B | 28.3B |
| Cost and Expenses | 22.6B | 21.7B | 14.3B | 19.3B | 34.2B |
| Operating Income (EBIT) | (19.3B) | (18.2B) | 791.0M | (9.8B) | (26.3B) |
| Non-Operating | |||||
| Interest Income | 1.1B | 1.3B | 210.7M | 669.2M | 536.7M |
| Interest Expense | 1.7B | 2.4B | 2.3B | 314.6M | 448.7M |
| Net Interest Income | (628.5M) | (1.1B) | (2.1B) | 354.6M | 88.0M |
| Other Non-Op Income/Expense | (5.3B) | (3.9B) | (7.7B) | (4.7B) | 9.7B |
| Non-Operating Income (excl Interest) | (263.4M) | — | 5.4B | 4.4B | (10.1B) |
| EBT (Pre-Tax Income) | (24.6B) | (22.1B) | (6.9B) | (14.5B) | (16.6B) |
| Income Tax Expense | 1.8B | 23.8M | (5.7B) | 1.0M | (805.5M) |
| Bottom Line | |||||
| Net Income | (26.5B) | (22.1B) | (6.9B) | (14.5B) | (15.8B) |
| Earnings from Cont. Ops | (26.5B) | (22.1B) | (1.2B) | (14.5B) | (15.8B) |
| Earnings from Discont. Ops | (158.6K) | — | — | — | — |
| Bottom Line Net Income | (26.5B) | (22.1B) | (6.9B) | (14.5B) | (15.8B) |
| Per Share | |||||
| Basic EPS | (₩275) | (₩230) | (₩87) | (₩172) | (₩189) |
| Diluted EPS | (₩275) | (₩230) | (₩87) | (₩172) | (₩189) |
| Revenue Per Share | ₩35 | ₩37 | ₩189 | ₩112 | ₩94 |
| Shares | |||||
| Basic Shares Outstanding | 96.1M | 96.0M | 79.6M | 84.5M | 83.6M |
| Diluted Shares Outstanding | 96.1M | 96.0M | 79.6M | 84.5M | 83.6M |
| Profitability Metrics | |||||
| EBITDA | (17.8B) | (16.9B) | (4.0B) | (12.7B) | (24.5B) |
| D&A | 1.4B | 1.3B | 633.8M | 1.4B | 1.8B |
| EBIT | (19.3B) | (18.2B) | (4.6B) | (14.2B) | (26.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026